Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
9 hedge funds and large institutions have $16.4M invested in Soleno Therapeutics in 2018 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 4 closing their positions.
3% more capital invested
Capital invested by funds: $15.9M → $16.4M (+$473K)
2.83% less ownership
Funds ownership: 5.97% → 3.14% (-2.8%)
18% less funds holding
Funds holding: 11 → 9 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$216K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.1K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$4.96K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.31K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$39K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$29K |
| 3 |
JP Morgan Chase
New York
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VC
1
Vivo Capital
Palo Alto,
California
| $7.31M | – | – | – |
|
|
OIM
2
Oracle Investment Management
Greenwich,
Connecticut
| $4.33M | – | – | – |
|
|
SM
3
Sabby Management
Miami Beach,
Florida
| $1.66M | +$4.96K | +182 | +0.3% |
|
|
6CM
4
683 Capital Management
New York
| $1.53M | – | – | – |
|
|
BC
5
Birchview Capital
Burlington,
Vermont
| $1.23M | – | – | – |
|
|
6
DZ Bank
Frankfurt Am Main,
Germany
| $215K | +$216K | +7,920 | New |
|
|
7
Vanguard Group
Malvern,
Pennsylvania
| $90K | +$17.1K | +627 | +23% |
|
8
BlackRock
New York
| $28K | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| $4K | +$4.31K | +158 | New |
|
|
TSS
10
Two Sigma Securities
New York
| – | -$39K | -1,432 | Closed |
|
|
11
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$29K | -1,080 | Closed |
|
|
12
JP Morgan Chase
New York
| – | -$2K | -60 | Closed |
|
SLNO Hedge Fund Activity: Q1 2018 in Review
9 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q1 2018, worth a combined $16.4M — up 3% from $15.9M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SLNO and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was DZ Bank, opening a new position worth an estimated $216K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $39K sold.
- 9 institutional investors held Soleno Therapeutics (SLNO) as of Q1 2018, down from 11 in Q4 2017.
- Funds reported $16.4M of Soleno Therapeutics stock for Q1 2018, up 3% quarter-over-quarter.
- 2 funds opened new Soleno Therapeutics positions in Q1 2018 and 4 closed out, a net change of -2 holders.
- The largest Soleno Therapeutics buyer in Q1 2018 was DZ Bank, an estimated $216K added.
- The largest Soleno Therapeutics seller in Q1 2018 was Two Sigma Securities, an estimated $39K sold.
Based on aggregated 13F filings for Q1 2018.